Frost & Sullivan Lauds FCMB ApS for Its Breakthrough Work in Non-invasive Prenatal Testing

LONDON, June 30, 2010 - Frost & Sullivan is pleased to announce that it has awarded its
prestigious 2010 Scandinavia New Product Innovation Award to FCMB ApS
("FCMB") for its breakthrough work in non-invasive prenatal testing. FCMB is
developing a suite of non-invasive prenatal diagnostics based on isolating
fetal cells from maternal blood samples. FCMB's diagnostics have the
potential to provide results that are as accurate as more invasive
procedures, such as amniocentesis and chronic villus sampling (CVS), without
the risk of miscarriage or other fetal damage.

(Logo: photos.prnewswire.com/prnh/20081117/FSLOGO)

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The scientific community has known for many decades that fetal cells
circulating in maternal blood could be utilized to diagnose genetic
abnormalities. However, isolating these cells is difficult given their
extreme scarcity. Taking a novel approach to this problem, FCMB has developed
a proprietary technology that allows for the collection and preservation of
fetal cells from maternal blood samples. These cells can be subsequently
analyzed using standard molecular biology procedures to determine genetic
abnormalities in a non-invasive fashion.

"We are quite excited about the about the opportunity ahead of us in
prenatal testing," says Dr. Andreas Eckelt, Chief Executive Officer of FCMB.
"We believe that our technology has the potential to significantly improve
the standard of care, while providing meaningful cost advantages to the
healthcare system."

Under current guidelines, parents of unborn children and the medical
community face a dilemma when it comes to prenatal testing. Non-invasive
diagnostic techniques, such as ultrasound or maternal serum sampling, can
only provide risk stratification, as they lack specificity and can identify
only predominant genetic aberrations. Invasive techniques, such as
amniocentesis or CVS, provide conclusive results, but also carry a 1-2 per
cent risk of miscarriage. Because of this risk, invasive testing is currently
limited to approximately 5 per cent of pregnant women.

"Given the unmet need in the multi-billion dollar market for prenatal
diagnostics, there is a race to commercialize new technologies," says Frost &
Sullivan Senior Research Analyst, Arun.A.K. "While FCMB's technology has yet
to be commercialized, we believe that it has the potential to offer
substantial accuracy advantages over other non-invasive techniques, as well
as significant safety advantages over more invasive procedures."

FCMB intends to offer its diagnostic testing using a service-based model.
FCMB believes that the accuracy and risk profile of its diagnostics, combined
with competitive pricing and the relative simplicity of a blood draw, will
result in rapid adoption by the medical community. FCMB's first test is for
Down's syndrome (Trisomy 21), which occurs in approximately one in 800 births
and is characterized by lifelong intellectual and developmental disabilities.
FCMB also has plans to expand its product offering to other genetic
abnormalities such as Edward's syndrome (Trisomy 18), Patau syndrome (Trisomy
13) and Klinefelter syndrome.

Each year, Frost & Sullivan presents this award to a company that has
developed an innovative element in a product by leveraging cutting-edge
technologies. The award recognizes the value added features and benefits of
the product and the increased return on investment it offers customers, which
in turn increases customer acquisition and overall market penetration
potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development. Industry analysts
compare market participants and measure performance through in-depth
interviews, analysis, and extensive secondary research in order to identify
best practices in the industry.

About FCMB ApS

FCMB was founded in 2005 with the vision of developing the first
non-invasive prenatal diagnostics technology platform based on the capture of
fetal cells in maternal circulation. FCMB has raised venture funding from
Inventure Capital and Oestjvsk Innovation. FCMB has 15 employees and is based
in Vejle, Denmark.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best-practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 40 offices on six continents. To join our Growth Partnership,
please visit www.awards.frost.com.

    Contact:

    Chiara Carella
    Corporate Communications - Europe
    P: +44(0)207-3438314
    E: chiara.carella@frost.com

www.frost.com

Chiara Carella, Corporate Communications - Europe, Frost & Sullivan, +44(0)207-3438314, chiara.carella at frost.com